Back to Journals » The Application of Clinical Genetics » Volume 13

Hutchinson–Gilford Progeria Syndrome: Clinical and Molecular Characterization

Authors Pachajoa H, Claros-Hulbert A, García-Quintero X, Perafan L, Ramirez A, Zea-Vera AF

Received 15 November 2019

Accepted for publication 13 May 2020

Published 4 September 2020 Volume 2020:13 Pages 159—164


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Martin H. Maurer

Harry Pachajoa,1,2 Angelica Claros-Hulbert,3,4 Ximena García-Quintero,3,4 Lina Perafan,1 Andres Ramirez,5 Andres F Zea-Vera6

1Faculty of Health Sciences, Congenital Anomalies and Rare Diseases Investigation Center (CIACER), Universidad Icesi, Cali, Colombia; 2Genetic Department, Fundacion Valle del Lili, Cali, Colombia; 3Pediatric Palliative Care Department, Fundacion Valle del Lili, Cali, Colombia; 4Clinical Investigation Center (CIC), Fundacion Valle del Lili, Cali, Colombia; 5Faculty of Health Sciences, Praxis Jessen² + Kollegen, Berlin, Germany; 6Faculty of Health Sciences, Universidad del Valle, Cali, Colombia

Correspondence: Harry Pachajoa Tel +57 3005757597

Abstract: Hutchinson–Gilford progeria syndrome (HGPS) is a rare congenital disease caused by mutations in the LMNA gene. Children with HGPS are phenotypically characterized by lipodystrophy, short height, low body weight, scleroderma, reduced joint mobility, osteolysis, senile facial features, and cardiovascular compromise that usually lead to death. We aimed to describe the case of a patient who reached above-average age expectancy for children with HGPS in Latin America and describe the clinical and molecular characteristics of the patient. A 14-year-old female patient was presented with progeria-compatible phenotypic characteristics. HGPS was confirmed via LMNA gene sequencing that detected a heterozygous c.1824C>T (p.Gly608Gly) mutation. The primary aim is to describe the HGPS case, the molecular gene mutation finding, and make a short review of the limited available treatment options for children with HGPS. Such as the farnesyl transferase inhibitors in conjunction with other pharmacological therapies that have insinuated improvement in health, and survival rate.

Keywords: HGPS, progeria, premature aging, genetic assessment, laminopathy, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]